Lantern Pharma (NASDAQ: LTRN) reported fourth-quarter and full-year 2025 operational highlights, underscoring continued progress in its AI-driven oncology pipeline. The company’s LP-300 Phase 2 HARMONIC trial has advanced with targeted enrollment completed in Japan, and protocol discussions with the U.S. Food and Drug Administration are planned for mid-May 2026. These milestones reflect Lantern’s commitment to accelerating the development of targeted cancer therapies using artificial intelligence.
Beyond LP-300, the company is advancing LP-184, LP-284, and STAR-001 across multiple oncology indications. The AI-driven portfolio now targets an estimated annual market opportunity exceeding $15 billion. Central to this effort is Lantern’s proprietary RADR® platform, which leverages machine learning to uncover novel therapeutic opportunities and streamline drug development. Additionally, the newly introduced withZeta.ai multi-agentic co-scientist platform is expanding commercial potential, with beta testing underway at more than 25 biotech companies, cancer research centers, and biopharma consultants.
Lantern ended 2025 with approximately $10.1 million in cash, cash equivalents, and marketable securities, providing a runway to support upcoming milestones. The company’s focus on AI-driven drug discovery positions it to address significant unmet needs in oncology, potentially improving patient outcomes while reducing development timelines and costs.
For more details, the full press release is available at https://ibn.fm/nDpjO. Lantern Pharma is an AI-driven biotechnology company dedicated to transforming cancer therapy through its RADR® platform. Updates and news about Lantern Pharma can be found in the company’s newsroom at https://ibn.fm/LTRN.
The implications of these developments are significant. By leveraging AI to identify and advance drug candidates, Lantern Pharma aims to address a $15 billion market opportunity while potentially bringing more effective treatments to patients faster. The planned FDA discussions for LP-300 and the expansion of the withZeta.ai platform signal the company’s strategic focus on both regulatory progress and commercial partnerships. As the oncology landscape evolves, Lantern’s AI-driven approach could set a precedent for how biotechnology companies accelerate drug development and improve patient outcomes.
